In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $34.54 in the prior trading day, Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) closed at $31.98, down -7.41%. In other words, the price has decreased by -$7.41 from its previous closing price. On the day, 0.68 million shares were traded.
Ratios:
Our goal is to gain a better understanding of TNXP by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.64 and its Current Ratio is at 12.31. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4.
ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 15 ’25 when LEDERMAN SETH bought 4,000 shares for $21.55 per share. The transaction valued at 86,200 led to the insider holds 4,005 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 23.43 while its Price-to-Book (P/B) ratio in mrq is 1.22.
Stock Price History:
Over the past 52 weeks, TNXP has reached a high of $137.25, while it has fallen to a 52-week low of $6.76. The 50-Day Moving Average of the stock is 28.72%, while the 200-Day Moving Average is calculated to be 50.95%.
Shares Statistics:
A total of 7.36M shares are outstanding, with a floating share count of 7.35M. Insiders hold about 0.07% of the company’s shares, while institutions hold 6.58% stake in the company.
Earnings Estimates
A detailed examination of Tonix Pharmaceuticals Holding Corp (TNXP) is currently in progress, with 1.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$2.75, with high estimates of -$2.75 and low estimates of -$2.75.
Analysts are recommending an EPS of between -$10.3 and -$10.3 for the fiscal current year, implying an average EPS of -$10.3. EPS for the following year is -$4.59, with 2.0 analysts recommending between -$4.5 and -$4.67.
Revenue Estimates
3 analysts predict $2.6M in revenue for the current quarter. It ranges from a high estimate of $2.7M to a low estimate of $2.5M. As of the current estimate, Tonix Pharmaceuticals Holding Corp’s year-ago sales were $2.21MFor the next quarter, 3 analysts are estimating revenue of $3.3M. There is a high estimate of $4.7M for the next quarter, whereas the lowest estimate is $2.5M.
A total of 3 analysts have provided revenue estimates for TNXP’s current fiscal year. The highest revenue estimate was $14.88M, while the lowest revenue estimate was $10.6M, resulting in an average revenue estimate of $12.16M. In the same quarter a year ago, actual revenue was $10.09MBased on 3 analysts’ estimates, the company’s revenue will be $81.7M in the next fiscal year. The high estimate is $166.1M and the low estimate is $31.3M.
